In this paper, a novel high-sensitivity broadband rectifier is proposed aiming at ambient radio frequency (RF) energy harvesting. Traditionally, voltage doubling rectifying circuit is used to design high-sensitivity rectifier. But when the input power is lower, the rectifying efficiency is significantly reduced. Therefore, an improved parallel half-wave rectifying circuit is proposed in this article which can convert RF energy in the whole period. And the proposed rectifying circuit can work better in lower power environment and has a higher efficiency level. Besides, the impedance match is also important component of rectifier. Due to the nonlinearity and complexity of rectifying circuit, achieving wideband matching network is a challenge. Thus, a design approach of broadband impedance circuit is given in this study. Combining with the proposed highsensitivity rectifying circuit, a high-sensitivity wideband rectifier can be generated, when the input power is -15 dBm, -20 dBm, -25 dBm, the efficiency is 43%, 32%, 20%, respectively. Finally, a second-order wideband rectifier with high sensitivity is realized, and the range of bandwidth can cover four main frequency bands of GSM 900 MHz, GSM 1800 MHz, UMTS 2100 MHz, WLAN 2400 MHz. To verify the validity, the rectifier is fabricated and measured, and the measurement has a good agreement with simulation results.

Background: Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated about 50~60% of response rate in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma. However, antigen-escape relapse has emerged as a major challenge for long-term disease control after CD19-targeted therapies. In our previous study, we described a dual-targeted of CD19 and CD22 CAR-T cell cocktail therapy, whichyielded 93.3% of complete remission (CR) rate in R/R B-cell acute lymphoblastic leukemia and could reduce the risk of CD19-negative relapse. Aims:Aims: A phase I/II clinical trial (NCT05206071) was designed to explore the safety and efficacy of CAR19/22 Tcell cocktail therapy for patients with R/R aggressive B-cell lymphoma. Methods:Methods: Eligible R/R aggressive B-cell lymphoma patients were enrolled from July 2020 toDecember 2021. All patients received fludarabine 30 mg/m2/d and cyclophosphamide 250 mg/m2/d for 3 consecutive days (day −5 to day −3) followed by cocktail CAR-T cell infusion. CAR-T-cell-related cytokine release syndrome (CRS) was graded to assess the safety. PET-CT was performed on day 28 and 3rd month to evaluate the response rate. Results: Results:A total of 26 eligible patients received CAR19/22 cocktail infusion with a median age of 46 years old (4-75) and a median of 3 prior lines of therapies (2-5 lines). Of 26 patients, 4 were Burkitt lymphoma, 2 were follicular lymphoma (grade 3a), and the rest were diffuse large B-cell lymphoma. Besides, 7 patients were diagnosed with double-hit lymphoma and 4 patients were relapsed after previous CD19 CAR-T cell therapy.Fourteen patients received the murinized CAR-T cells at a median dose of 2.18×10 6 /kg (1-3×10 6 /kg) CAR19 and 1.75×10 6 /kg (1-3×10 6 /kg) CAR22, while 12 patients received the does of the humanized CAR-T cells consisting of 2×10 6/ kg CAR19 and 5×10 5 /kg CAR22.At the day 28 assessment, 12/12 (100%) patients received the humanized CAR-T cells achieved overall response, including 9/12 (75%) CR and 3/12 (25%) partial remission (PR), while the overall response rate (ORR) and CR rate of the murinized group was 85.71% (12/14) and 42.86% (6/14) respectively. Among of them, all 4 Burkitt lymphoma patients in both groups achieved CR. In 3 months evaluation, 7/10 (70%,2 cases received infusion for less than 3 months) patients in the humanized group maintained in CR, which was higher than the murinized group with CR rate of 5/14 (35.71%). (Figure 1A-B). At a median follow-up of 291 days (range, 31 to 544), patients in the humanized group had a favorable progression-free survival (PFS) than those in the murinized (1-year PFS of 67.9% vs. 26.8%), although there was no statistical significance (p=0.08) due to the limited number of patients enrolled (Figure 1E-F). Achieving CR on day 28 (HR: 0.21, 95% CI: 0.06-0.72; P=0.012) and maintaining CR till the 3rd month (HR: 0.18, 95% CI: 0.06-0.59; P=0.004) were found as independent prognostic factors associated with favorable PFS. Maintaining CR till the 3rd month (HR: 0.10, 95% CI: 0.01-0...